IP Verse

Compositions And Methods Of Treating Inflammatory And Autoimmune Diseases - EP2382228

The patent EP2382228 was granted to Amgen on Aug 26, 2020. The application was originally filed on Jan 20, 2010 under application number EP10733814A. The patent is currently recorded with a legal status of "Granted And Under Opposition".

EP2382228

AMGEN
Application Number
EP10733814A
Filing Date
Jan 20, 2010
Status
Granted And Under Opposition
Jul 24, 2020
Grant Date
Aug 26, 2020
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (6)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

KONIG SZYNKA TILMANN VON RENESSEMay 26, 2021KONIG SZYNKA TILMANN VON RENESSE DUSSELDORFADMISSIBLE
KONIG SZYNKA TILMANN VON RENESSEMay 26, 2021KONIG SZYNKA TILMANN VON RENESSE PATENTANWALTE PARTNERSCHAFT MBB DUSSELDORFADMISSIBLE
MERCK SHARP & DOHMEMay 26, 2021MERCK SHARP & DOHMEADMISSIBLE
SANOFIMay 25, 2021CABINET NONYADMISSIBLE
SANOFIMay 25, 2021IPSILONADMISSIBLE
STRAWMANMay 25, 2021MEWBURN ELLISWITHDRAWN

Patent Citations (25) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONEP0338841
DESCRIPTIONUS2003195154
DESCRIPTIONUS2005142106
DESCRIPTIONUS4470461
DESCRIPTIONUS4588585
DESCRIPTIONUS5122464
DESCRIPTIONUS6955807
INTERNATIONAL-SEARCH-REPORTUS2005142106
OPPOSITIONEP0262802
OPPOSITIONEP2382228
OPPOSITIONUS2003195154
OPPOSITIONUS2005142106
OPPOSITIONUS2011150826
OPPOSITIONUS5466447
OPPOSITIONWO03015697
OPPOSITIONWO2005007121
OPPOSITIONWO2005086798
OPPOSITIONWO2008003473
OPPOSITIONWO2009061853
OPPOSITIONWO2009135615
OPPOSITIONWO2010021519
OPPOSITIONWO2010085495
OPPOSITIONWO9320849
OPPOSITIONWO9960128
SEARCHUS2005142106

Non-Patent Literature (NPL) Citations (79) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- HU, W. S.; AUNINS, J. G., "Large-scale Mammalian Cell Culture", CURR OPIN BIOTECHNOL, (1997), vol. 8, pages 148 - 153-
DESCRIPTION- KAUFMAN; SHARP, "Construction Of A Modular Dihydrafolate Reductase cDNA Gene: Analysis Of Signals Utilized For Efficient Expression", MOL. CELL. BIOL., (1982), vol. 2, pages 1304 - 1319, XP001007141-
DESCRIPTION- RAO ET AL., BIOCHEMISTRY, (2005), vol. 44, pages 10696 - 10701-
DESCRIPTION- "Unit 6.5", Current Protocols in Protein Science, JOHN WILEY AND SONS, INC, (1997), vol. 2-
DESCRIPTION- XINQUAN WANG; MATHIAS RICKERT; K. CHRISTOPHER GARCIA, SCIENCE, (2005), vol. 310, page 1159-
DESCRIPTION- MATHER, J. P., "Laboratory Scaleup of Cell Cultures (0.5-50 liters)", METHODS CELL BIOLOG, (199802), vol. 57, no. 57, doi:doi:10.1016/S0091-679X(08)61581-2, pages 219 - 227, XP008093720
DESCRIPTION- KONSTANTINOV, K. B. ET AL, "Control of long-term perfusion Chinese hamster ovary cell culture by glucose auxostat.", BIOTECHNOL PROG, (1996), vol. 12, doi:doi:10.1021/bp950044p, pages 100 - 109, XP002285656
DESCRIPTION- MARK, "Site-specific Mutagenesis Of The Human Fibroblast Interferon Gene", PROC. NATL. ACAD. SCI. USA, (1984), vol. 81, doi:doi:10.1073/pnas.81.18.5662, pages 5662 - 5666, XP002554304
EXAMINATION- "Human mature interleukin-2 mutein N88D/C125S.", Geneseq, (20051201), Database accession no. AEC77664, URL: EBI-
EXAMINATION- L. Passerini ET AL, "STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells", International Immunology, (20080212), vol. 20, no. 3, doi:10.1093/intimm/dxn002, ISSN 0953-8178, pages 421 - 431, XP055193539-
EXAMINATION- Adrian Liston ET AL, "Tracing the action of IL-2 in tolerance to islet-specific antigen", IMMUNOLOGY AND CELL BIOLOGY, AU, (20070320), vol. 85, no. 4, doi:10.1038/sj.icb.7100049, ISSN 0818-9641, pages 338 - 342, XP055440748
EXAMINATION- Katrina Hoyer ET AL, "Interleukin-2 in the development and control of inflammatory disease", Immunological Reviews, doi:10.1111/j.1600-065X.2008.00697.x, (20081201), pages 19 - 28, URL: http://onlinelibrary.wiley.com/store/10.1111/j.1600-065X.2008.00697.x/asset/j.1600-065X.2008.00697.x.pdf?v=1&t=jcbyqatv&s=e7a02fe959ab86a7a631639395d9d53026d7ab2d, (20180112), XP055440534
INTERNATIONAL-SEARCH-REPORT- FUJII ET AL., "Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission.", PNAS, (1995), vol. 92, pages 5482 - 5486-
INTERNATIONAL-SEARCH-REPORT- NAGASE ET AL., "Despite increased CD4+Foxp3+ cells within the infection site, BALB/c IL-4 receptor-deficient mice reveal CD4+ Foxp3-negative T cells as a source of IL-10 in Leishmania major susceptibility.", JOURNAL OF IMMUNOLOGY, (2007), vol. 179, pages 2435 - 2444-
OPPOSITION- ALLAN et al., "Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production", International Immunology, (20070000), vol. 19, no. 4, pages 345 - 354, XP055813484-
OPPOSITION- Bachmann Martin F., Annette Oxenius, "Interleukin 2: from immunostimulation to immunoregulation and back again", EMBO Reports, (20070000), vol. 8, pages 1142 - 1148, XP055813362-
OPPOSITION- Balaji Rao, "Interleukin-2 Engineering for Improved Therapeutic Effectiveness", Massachusetts Institute of Technology PhD, (20040000), pages 1 - 106, XP055813372-
OPPOSITION- BENSINGER et al., "Distinct IL-2 receptor signaling pattern in CD4+CD25+ regulatory T cells", J. Immunol., (20090000), vol. 172, no. 9, pages 5287 - 5296, XP002493084-
OPPOSITION- BOYMAN et al., "Potential use of IL-2/anti-IL-2 antibody immune complexes for the treatment of cancer and autoimmune disease", Expert Opin. Biol. Ther., (20060000), vol. 6, no. 12, pages 1323 - 1331, XP002457767-
OPPOSITION- BRUSKO et al., "Human regulatory t-cells: role in autoimmune disease and therapeutic opportunities", Immunological Reviews, (20080000), vol. 223, pages 371 - 390, XP002596194-
OPPOSITION- BRUSKO TODD M; PUTNAM AMY L; BLUESTONE JEFFREY A, "Human regulatory T cells: role in autoimmune disease and therapeutic opportunities", Immunological Reviews, (20080000), vol. 223, pages 371 - 390, XP002596194-
OPPOSITION- Dennis Adeegbe, Allison L. Bayer, Robert B. Levy, Thomas R. Malek, "Cutting edge: Allogeneic CD4+CD25+Foxp3+ T regulatory cells suppress autoimmunity while establishing transplantation tolerance", J. Immunol., (20060000), vol. 176, pages 7149 - 7153, XP055811184-
OPPOSITION- EISENSTEIN et al., "The T(reg)/Th17 cell balance: a new paradigm for autoimmunity", Pediatr Res, (20090500), vol. 65, no. 5, pages 26R - 31R, XP055810888-
OPPOSITION- FUJI et al., "Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission", PNAS, USA, (19950000), vol. 92, pages 5482 - 5486, XP055474692-
OPPOSITION- Hodaka Fujii; Nakagawa Yoko; Schindleri Ulrike; Kawahara Atsuo; Mori Hisashi; Gouilleux Fabrice; Groner Bernd; Ihlei James N; Minami Yasuhiro; Taniguchi Tadatsugu, "Activation of Stat5 by interleukin 2 requires a carboxyl-terminal region of the interleukin 2 receptor beta chain but is not essential for the proliferative signal transmission", Proc Natl Acad Sci USA, (19950606), vol. 92, no. 12, pages 5482 - 5486, XP055474692-
OPPOSITION- IMAMICHI et al., "IL-15 acts as a potent inducer of CD4(+)CD25(hi) cells expressing FOXP3", Eur. J. Immunol, (20080000), vol. 38, no. 6, pages 1621 - 1630, XP055811106-
OPPOSITION- J Adam Rindfleisch, "Diagnosis and management of rheumatoid arthritis", AMERICAN FAMILY PHYSICIAN, American Academy of Family Physicians, US, US , (20050915), vol. 72, no. 6, ISSN 0002-838X, pages 1037 - 1047, XP093166849-
OPPOSITION- Jiang, "Chapter 2, 3, 5, and 8", Regulatory Cells and Clinical Application, (20080000), pages 17, 19, 20, 29, 43. 58, 70 - 77-78, 80, 94, 97, 135-136 and 261, XP055813524-
OPPOSITION- LEIPE et al., "Regulatory T cells in rheumatoid arthritis", Arthritis Res Ther., (20050000), vol. 7, no. 3, pages 93 - 99, XP055813478-
OPPOSITION- LUI et al., "Engineered interleukin-2 antagonists for the inhibition of regulatory T cells", J. Immunother., (20090000), vol. 32, no. 9, pages 887 - 894, XP055811172-
OPPOSITION- PANDIYAN et al., "CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells", Nat Immunol., (20071200), vol. 8, no. 12, pages 1353 - 1362, XP055810877-
OPPOSITION- Passerini L; Allan S E; Battaglia M; Di Nunzio S; Alstad A N; Levings M K; Roncarolo M G; Bacchetta R, "STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells", International Immunology, (20080000), vol. 20, no. 3, pages 421 - 431, XP055193539-
OPPOSITION- Passerini L; Allan S E; Battaglia M; Di Nunzio S; Alstad A N; Levings M K; Roncarolo M G; Bacchetta R, "STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells", International Immunology, (20080301), vol. 20, no. 3, pages 421 - 431, XP055193539-
OPPOSITION- Passerini L; Allan S E; Battaglia M; Di Nunzio S; Alstad A N; Levings M K; Roncarolo M G; Bacchetta R, "STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells", Int Immunol., (20080000), vol. 20, no. 3, pages 421 - 431, XP055193539-
OPPOSITION- SHEVACH, "Mechanisms of Fop3+ T Regulatory Cell-Medieted Suppression", Immunity, (20090000), vol. 30, no. 5, pages 636 - 645, XP055813474-
OPPOSITION- TANG et al., "Central role of defective interleukin-2 production in triggering islet autoimmune destruction", Immunity, (20080000), vol. 28, no. 5, pages 687 - 697, XP055813498-
OPPOSITION- Tran D Q; Ramsey H; Shevach E M, "Induction of FOXP3 expression in naive human CD4+FOXP3 T cells by T-cell receptor stimulation is transforming growth factor- dependent but does not confer a regulatory phenotype", Blood, (20070000), vol. 110, no. 8, pages 2983 - 2990, XP055591396-
OPPOSITION- VALENCIA et al., "CD4+CD25+FoxP3+ regulatory T cells in autoimmune diseases", Nat Clin Pract Rheumatol, (20071100), vol. 3, no. 11, pages 619 - 626, XP055810847-
OPPOSITION- Wynn Thomas A, "Common and unique mechanisms regulate fibrosis in various fibroproliferative diseases.", The Journal of Clinical Investigation, B M J Group, (20070301), vol. 117, no. 3, pages 524 - 529, XP009137678-
OPPOSITION- ZEISER et al., "Differential impact of mammalian target of rapamycin inhibition on CD4+CD25+Foxp3+ regulatory T cells compared with conventional CD4+ T cells", Blood, (20080000), vol. 11, no. 1, pages 453 - 462, XP055811164-
OPPOSITION- ZORN EMMANUEL; ET AL, "IL-2 regulates FOXP3 expression in human CD4(+)CD25(+) regulatory T cells through a STAT-dependent mechanism and induces the expansion of these cells in vivo", Blood, (20060000), vol. 108, no. 5, pages 1571 - 1579, XP002434925-
OPPOSITION- HEATON et al., "CHARACTERIZATION OF LYMPHOKINE-ACTIVATED KILLING BY HUMAN PERIPHERAL BLOOD MONONUCLEAR CELLS STIMULATED WITH INTERLEUKIN 2 (IL-2) ANALOGS SPECIFIC FOR THE INTERMEDIATE AFFINITY IL-2 RECEPTOR", Cellular Immunology, (19930000), vol. 147, no. 1, pages 167 - 179, XP000565560
OPPOSITION- Sporn, M.B. ; Harris, E.D., "Proliferative Diseases", AMERICAN JOURNAL OF MEDICINE., Excerpta Medica, Inc., United States, United States , (19810601), vol. 70, no. 6, doi:10.1016/0002-9343(81)90832-9, ISSN 0002-9343, pages 1231 - 1236, XP026386403
OPPOSITION- SAKAGUCHI et al., "Regulatory T cells and immune tolerance", Cell, (20080000), vol. 133, no. 5, doi:10.1016/j.cell.2008.05.009, pages 775 - 787, XP002582219
OPPOSITION- Albanesi, C. De Pita, O. Girolomoni, G., "Resident skin cells in psoriasis: a special look at the pathogenetic functions of keratinocytes", CLINICS IN DERMATOLOGY., J.B. LIPPINCOTT, PHILADELPHIA, PA., US, US , (20071101), vol. 25, no. 6, doi:10.1016/j.clindermatol.2007.08.013, ISSN 0738-081X, pages 581 - 588, XP022342595
OPPOSITION- Rieder, F. ; Fiocchi, C., "Intestinal fibrosis in inflammatory bowel disease - Current knowledge and future perspectives", Journal of Crohn's and Colitis, Elsevier BV, NL, NL , (20081201), vol. 2, no. 4, doi:10.1016/j.crohns.2008.05.009, ISSN 1873-9946, pages 279 - 290, XP025692409
OPPOSITION- Chen; Khurana Hershey W; G K, "Signal transducer and activator of transcription signals in allergic disease", J Allergy Clin Immunol, (20070000), vol. 119, no. 3, pages 529 - 541, XP005906435
OPPOSITION- Letourneau S; Krieg C; Pantaleo G; Boyman O, "IL-2- and CD25-dependent immunoregulatory mechanisms in the homeostasis of T-cell subsets", J Allergy Clin Immunol, (20090400), vol. 123, no. 4, pages 758 - 762, XP026068372
OPPOSITION- LAN et al., "The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)", J Autoimmun, (20080000), vol. 31, no. 1, pages 7 - 12, XP002687866
OPPOSITION- LAN et al., "The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)", Journal of Autoimmunity, (20080000), vol. 31, no. 1, pages 7 - 12, XP002687866
OPPOSITION- LAN et al., "The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)", Journal of Autoimmunity, (20080000), vol. 31, pages 7 - 12, XP002687866
OPPOSITION- Balaji M Rao; Ian Driver; Douglas A Lauffenburger; Dane Wittrup K, "High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth", Biochemistry, (20050000), vol. 44, no. 31, pages 10696 - 10701, XP002628067
OPPOSITION- Balaji M Rao; Ian Driver; Douglas A Lauffenburger; Dane Wittrup K, "High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth", Biochemistry, (20050000), vol. 44, pages 10696 - 10701, XP002628067
OPPOSITION- Balaji M Rao; Ian Driver; Douglas A Lauffenburger; Dane Wittrup K, "High-Affinity CD25-Binding IL-2 Mutants Potently Stimulate Persistent T cell Growth", Ph.D Thesis, (20040000), pages 10696 - 10701, XP002628067
OPPOSITION- SHANAFELT et al., "A T-cell-selective interleukin 2 mutein exhibits potent antitumor activity and is well tolerated in vivo", Nature Biotechnology, (20000000), vol. 18, no. 11, pages 1197 - 1202, XP002307306
OPPOSITION- GOODSON R J; NANDINI V KATRE, "SITE-DIRECTED PEGYLATION OF RECOMBINANT INTERLEUKIN-2 AT ITS GLYCOSYLATION SITE", Biotechnology, N Y, (19900000), vol. 8, no. 4, pages 343 - 346, XP000563746
OPPOSITION- Gill Adams; Vessillier Sandrine, "Targeting cytokines to inflammation sites", Nat Biotechnol, (20030000), vol. 21, no. 11, pages 1314 - 20, XP055676803
OPPOSITION- MALEK et al., "Tolerance, not immunity crucially depends on IL-2", Annu. Rev. Immunol., (20080000), vol. 26, pages 453 - 479, XP055314630
OPPOSITION- Thomas R. Malek & Allison L. Bayer, "Tolerance, not immunity, crucially depends on IL-2", Annu Rev Immunol, (20080000), vol. 26, pages 453 - 479, XP055314630
OPPOSITION- Thomas R Malek; Allison L Bayer, "Tolerance, not immunity, crucially depends on IL-2", Nature Reviews: Immunology, (20040000), vol. 4, no. 9, pages 665 - 674, XP055314630
OPPOSITION- LISTON et al., "Tracing the action of IL-2 in tolerance to islet-specific antigen", Immunology and Cell Biology, (20070000), vol. 85, no. 4, pages 338 - 342, XP055440748
OPPOSITION- HUMRICH et al., "Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus", Proc Natl Acad Sci USA, (20100000), vol. 107, no. 1, pages 204 - 209, XP002787802
OPPOSITION- Jens Y Humrich , Henner Morbach, Reinmar Undeutsch, Philipp Enghard, Stefan Rosenberger, Olivia Weigert, Lutz Kloke, Juliane Heimann, Timo Gaber, Susan Brandenburg, Alexander Scheffold, Jochen Huehn, Andreas Radbruch, Gerd-Rüdiger Burmester, Gabriela Riemekasten, "Homeostatic imbalance of regulatory and effector T cells due to IL-2 deprivation amplifies murine lupus", Proceedings of the National Academy of Sciences, (20210521), pages 204 - 209, XP002787802
OPPOSITION- Webster K E; Walters S; Kohler R E; Mrkvan T; Boyman O; Surh C D; Grey S T; Sprent J, "In vivo expansion of T reg cells with IL-2-mAb complexes: induction of resistance to EAE and long-term acceptance of islet allografts without immunosuppression", J. Exp. Med., (20090000), vol. 206, no. 4, page 751, XP055183306
OPPOSITION- Liu David V; Maier Lisa M; Hafler David A; Wittrup K Dane, "Engineered Interleukin-2 Antagonists for the Inhibition of Regulatory T Cells", J Immunother, (20090000), vol. 32, pages 887 - 894, XP009145853
OPPOSITION- Jan J. Weening, "The classification of glomerulonephritis in systemic lupus erythematosus revisited", Kidney International, Elsevier, (20040201), vol. 65, no. 2, doi:10.1111/j.1523-1755.2004.00443.x, ISSN 0085-2538, pages 521 - 530, XP093166856
OPPOSITION- Hoyer Katrina K., Hans Dooms Luke Barron Abul K. Abbas, "Interleukin-2 in the development and control of inflammatory disease", Immunol Rev, (20080000), vol. 226, pages 19 - 28, XP055440534
OPPOSITION- Katrina Hoyer; Dooms Hans; Barron Luke; Abbas Abul K, "Interleukin-2 in the development and control of inflammatory disease", Immunological Review, (20080000), vol. 226, pages 19 - 28, XP055440534
OPPOSITION- WANG et al., "Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma(c) receptors", Science, (20050000), vol. 310, pages 1159 - 1163, XP002628065
OPPOSITION- WANG et al., "Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma(c) receptors", Science, (20051118), vol. 310, no. 5751, pages 1159 - 1163, XP002628065
OPPOSITION- Lance Cohen, "Epithelial Cell Proliferation Contributes to Airway Remodeling in Severe Asthma", American Thoracic Society 2020 International Conference; May 15-20, 2020, American Thoracic Society, (20070715), vol. 176, no. 2, doi:10.1164/rccm.200607-1062OC, ISSN 1073-449X, pages 138 - 145, XP093166852
OPPOSITION- Mark A. Crowther, "Pathogenesis of Atherosclerosis", American society of hematology, American society of hematology, Washington, DC, US, US , (20050101), vol. 2005, no. 1, doi:10.1182/asheducation-2005.1.436, ISSN 1520-4391, pages 436 - 441, XP093166854
OPPOSITION- AHMADZADEH et al., "IL-2 administration increases CD4+CD25hi Foxp3+ regulatory T cells in cancer patients", Blood, (20060000), vol. 107, no. 6, pages 2409 - 2414, XP055597547
OPPOSITION- Jalal A. Jazayeri & Graeme J. Carroll, "Fc-based cytokines: Prospects for engineering superior therapeutics", Biodrugs, (20080000), vol. 22, no. 1, pages 11 - 26, XP009148905
OPPOSITION- CASSELL et al., "THERAPEUTIC ENHANCEMENT OF IL-2 THROUGH MOLECULAR DESIGN", Current Pharmaceutical design, (20020000), vol. 8, no. 24, pages 2171 - 2183, XP001205312
SEARCH- LAN RUTH Y ET AL, "The regulatory, inflammatory, and T cell programming roles of interleukin-2 (IL-2)", JOURNAL OF AUTOIMMUNITY, (200808), vol. 31, no. 1, ISSN 0896-8411, pages 7 - 12, XP022673755 [Y] 1-18 * the whole document *
SEARCH- BALAJI M RAO ET AL, "High-affinity CD25-binding IL-2 mutants potently stimulate persistent T cell growth", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY, US, vol. 44, no. 31, doi:10.1021/BI050436X, ISSN 0006-2960, (20050801), pages 10696 - 10701, (20050714), XP002628067 [A] 1-18 * the whole document *
SEARCH- WANG XINQUAN ET AL, "Structure of the quaternary complex of interleukin-2 with its alpha, beta, and gamma(c) receptors", SCIENCE, AMERICAN ASSOCIATION FOR THE ADVANCEMENT OF SCIENCE, WASHINGTON, DC; US, (20051101), vol. 310, no. 5751, doi:10.1126/SCIENCE.1117893, ISSN 0036-8075, pages 1159 - 1163, XP002628065 [DA] 1-18 * the whole document *
SEARCH- MATEK THOMAS R, "The biology of interleukin-2", ANNUAL REVIEW OF IMMUNOLOGY, (2008), vol. 26, ISSN 0732-0582, pages 453 - 479, XP002687867 [A] 1-18 * the whole document *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents